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Abstract 
In this study febantel was dissolved under increased temperature in a non-ionic surfactant 
Lutrol L44®, and subsequently mixed into an aqueous maltodextrin solution. After 8h under 
static conditions, coacervation or phase separation took place. 1H-NMR spectra and HPLC 
analysis showed that the upper phase contained mainly all febantel, while no febantel was 
detected in the lower phase. Fluorescent microscopy showed that maltodextrin is distributed 
in the lower phase. Coacervation proved to be a promising formulation technology for certain 
poorly water-soluble drugs, such as febantel. The coacervate phase showed an increase in 
in vitro dissolution kinetics, compared to Rintal® granules. These results were confirmed in 
an in vivo study performed on dogs. Febantel and fenbendazole showed a significant 
increase in plasma concentration compared to Rintal® granules. Further studies have to be 
performed to transform coacervates into a solid dosage form and to prove broad applicability 
to other poorly soluble drugs. 
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1 INTRODUCTION 
As approximately 40% of the novel drug candidates are classified as class II and class IV 
drugs in the biopharmaceutical classification system, their development is hindered by poor 
water-solubility, limiting their bioavailability. Therefore, technologies aimed at improving their 
rate and extent of dissolution of poorly water-soluble drugs are continuously being developed 
[1]. Different methods to improve the water-solubility have been described in literature, such 
as the inclusion of drugs in cyclodextrins [2-5], solid dispersions [6], self-emulsifying drug 
delivery systems [7], nanocrystals [8, 9] and coacervation. Coacervation is defined as the 
separation of colloidal systems into two liquid phases (IUPAC). It can be distinguished from 
precipitation, which is observed in the form of coagulum or flocs and occurs in colloidal 
unstable systems [10].  Bungenberg et al. [11] defined coacervation as a process in which 
aqueous colloidal solutions separate, upon alteration of the thermodynamic condition of state, 
into two liquid phases, one rich in colloid, i.e. the coacervate, while the other contains little 
colloid.  
Drug formulation based on coacervate systems have already been reported, i.e a hydrogel-
based or foam-based aqueous coacervate system including a water-insoluble drug, an 
amphoteric surfactant and an edible mono-or polysaccharide acting as rigidifying agent for 
the gel or foam material [12, 13].  Another, biological application of a coacervate system, is a 
gelatin-based synthetic whole blood useful as a replacement for whole mammalian blood [14]. 
The aqueous two-phase coacervate system evaluated in this study consisted of the 
combination of a poorly water-soluble drug with a non-ionic tensioactive agent and a water-
soluble polysaccharide maltodextrin. 
The first purpose of this study was to examine the distribution of the poorly water-soluble 
drug in the two-phase coacervate system. The second purpose was to examine the in-vivo 
and in-vitro performance of the coacervate system as a formulation strategy for poorly water-
soluble drugs. For this purpose, febantel was used as an extremely poorly water-soluble (1-2 
ppm in water pH 5-9) broad-spectrum probenzimidazole that is widely used against 
gastrointestinal nematodes and lungworms in livestock. It is a prodrug that is metabolized in 
vivo to fenbendazole and further to oxfendazole, 4-hydroxyfenbendazole, 4-
hydroxyfendazole, and an inactive metabolite fenbendazolesulfone [15-17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 MATERIALS AND METHODS 
2.1 Materials 
Febantel was purchased from UTAG (Amsterdam, The Netherlands). Maltodextrin, with a 
dextrose equivalent of 8 (Pharmadry C*01983) was obtained from Cargill (Mechelen, 
Belgium). Lutrol L44® was obtained from BASF (Ludwigshafen, Germany). Rhodamine B 
Octadecyl ester was obtained from Fluka (Buchs, Switzerland). The deuterated solvents D2O 
and MeOH-d4 were obtained from Acros Organics (Geel, Belgium). 
 
2.2 Preparation of febantel coacervate 
For the preparation of the coacervate, Lutrol L44® (a block copolymer of ethyleneoxide and 
propyleneoxide, used as a non-ionic surfactant) (BASF, Ludwigshafen, Germany) was 
heated to 130°C, and febantel (UTAG, Amsterdam, The Netherlands) was dissolved in the 
heated Lutrol L44® phase in a 1/7 (w/w) ratio. The febantel/Lutrol solution (about 80°C) was 
added to an aqueous maltodextrin solution (42 %, w/w) and homogenized during 5 min using 
a high shear mixer (Silverson L4R, Chesham, England) operating at 6000 rpm. Finally, the 
liquid was allowed to stand under static conditions at room temperature for 8h to allow 
coacervate formation and phase separation. The batch size produced in these experiments 
was 100 g. TGA measurements (Hi-res TGA 2950, TA Instruments, Leatherhead, UK) were 
employed to investigate the thermal stability of febantel and Lutrol L44®. Samples (± 15 mg) 
were equilibrated at 50°C and heated to 300°C (febantel) or 500°C (Lutrol L44®) at heating 
rate of 10°C/min while recording weight loss. 
 
2.3 Characterization 
2.3.1 Fluorescence microscopy 
Fluorescence microscopy was used to determine the distribution of the respective 
components in the different phases of the coacervate system. For this purpose, the amount 
of material was downscaled with a factor 10. Fluorescent labelling of the febantel/Lutrol L44® 
phase was performed by addition of 1 μl of a 10 mg/ml rhodamine B octadecyl ester solution 
in ethanol, after complete dissolution of febantel in Lutrol L44®. The aqueous maltodextrin 
phase was fluorescently labelled by addition of 10 μl of a 1 mg/ml FITC-dextran solution in 
water. Using these phases a fluorescent coacervate system was formed as described in 
section 2.2. Fluorescence microscopy images were recorded on Leica DM2500P microscope 
equipped with 10 x and 63 x oil immersion objectives and a DFC360FX CCD camera. Hot 
stage microscopy was performed on the same microscope, equipped with a THMS600 
heating stage. 
2.3.2 1H-NMR spectroscopy 
1H-NMR spectra were recorded separately in D2O and/or MeOH-d4, depending on the 
solubility of the components. The 1H-NMR spectra were recorded on a 300 MHz Varian Inova 
spectrometer. Spectra were acquired with a 45° pulse of 5 μs, a spectral width of 4800 Hz, 
an acquisition time of 3 s, a preparation delay of 2 s and 64 accumulations. The chemical 
shift axis was calibrated by means of the D2O resonance at 4.64 ppm from tetramethylsilane. 
 
2.4 Release of febantel  
Hard-gelatin capsules (n°00) were loaded with 115 mg of febantel formulated as (a) physical 
mixture at room temperature of febantel and 1.39 g Lutrol L44®, (b) 1.5 g of coacervate and 
(c) 1.15 g of Rintal® granules(i.e. a commercially available granule formulation containing 10% 
febantel and sodium docusate). Febantel release from these formulations was subsequently 
determined using a USP Apparatus 1 (basket, 100 rpm) in 900 ml demineralized water (at 
37.5 °C). Samples of 5 ml were taken at 5, 10, 15, 20, 30, 45, 60 and 120 min.  Samples 
were analysed via high-pressure liquid chromatography (HPLC). The HPLC system (Merck-
Hitachi D-7000, Tokyo, Japan) consisted of a pump (Merck-Hitachi L-7200), an autosampler 
(Merck-Hitachi L-7250), a Halo Phenyl-Hexyl column (4.6 x 50 mm, 2.7 µm) (Advanced 
Materials Technology, Wilmington, USA), and an UV-detector (Merck-Hitachi L-7400) set at 
295 nm. For the preparation of the mobile phase 0.01 M ammonium dihydrogen phosphate 
(Merck, Darmstadt, Germany) was mixed with acetonitrile (Biosolve, Valkenswaard, the 
Netherlands) in a ratio 50/50 (vol/vol). The analyses were performed at ambient temperature 
and the flow rate was set at 1 ml/min.  A volume of 2 µl was injected onto the HPLC system. 
 
2.5 Bioavailability of febantel  
The study was approved by the Ethical Committee of the Faculty of Veterinary Medicine 
(Ghent University, Belgium). A cross-over study in dogs (n=4, body weight varying between 
20 and 40 kg) was performed to determine the bioavailability of febantel after oral 
administration of the febantel coacervate phase and Rintal® granules. The dogs received a 
hard-gelatin capsule containing 15 mg febantel per kg, formulated as the coacervate phase 
or Rintal® granules. The washout period between sessions was 2 weeks. Blood samples (2 
ml) were taken prior to each treatment day (= blank sample) and 0.5, 1, 2, 4, 8, 16, 24, 48 
and 72 h after administration by puncturing the vena jugularis. The blood samples were 
collected in dry heparinized tubes and within 1h after collection blood was centrifuged for 10 
min at 1500 g and kept frozen at -20°C until analysed. 
 
2.6 Determination of febantel plasma concentration   
Febantel, fenbendazole and oxfendazole plasma concentrations were determined based on 
the HPLC-MS method developed by De Ruyck et al.[18] using mebendazole as internal 
standard. The chromatographic system consisted of a Kontron instrument (Zurich, 
Switzerland). Separation was carried out using a Luna C18 Column (50 mm x 2.0 mm, 
particle size 3μm; Grace, Columbia, MD, USA). The injection volume was 10μl. Gradient 
elution was performed with a flow rate of 0.2 ml/min starting at 75% eluent A (water 
containing 0.1% formic acid). Eluent B (acetonitrile containing 0.1% formic acid) was linearly 
increased from 25% to 75% during 12 min. The initial conditions were regained over a 0.1 
min time interval, followed by a 5 min equilibration time prior to the next injection. This 
resulted in an overall run time of 17 min. Detection was performed using a Quattro II triple 
quadrupole mass spectrometer (Waters, Manchester, UK) equipped with an electrospray 
ionization source in the electrospray positive ion mode (ESI+). Nitrogen was used as both 
drying and nebulizing gas. Product ions were detected using the multiple reaction-monitoring 
(MRM) mode, using argon as collision gas. The capillary voltage and source temperature 
were optimized at 3.6 kV and 120°C, respectively. The collision energy and cone voltage 
were optimized for each compound individually. The collision energy varied from 17 eV to 30 
eV and the cone voltage varied from 35 V to 50 V. Data were collected and processed using 
the MassLynx and QuanLynx software 4.0 (Waters, Manchester, UK). The peak plasma 
concentration (Cmax), the time to reach Cmax (Tmax) and the extent of absorption (AUC0-12h) 
were determined.   
3 RESULTS AND DISCUSSION 
A first key step in our formulation strategy was the dissolution of the poorly water-soluble 
drug in a liquid surfactant phase. Febantel (Figure 1) was dissolved in Lutrol L44® by heating 
the liquid slightly above the melting point of febantel (i.e. 129 °C). TGA indicated an onset of 
thermal degradation of 160°C and 200°C for febantel and Lutrol L44®, respectively. These 
temperatures are well above the temperature of the coacervation process (data not shown). 
Figure 2A show photographs of test tubes filled with (A1) a Lutrol L44®/Febantel suspension 
prior to heating and (A2) a homogeneous liquid after heating. Further evidence that febantel 
effectively dissolved in a liquid Lutrol L44® phase was gained via hot stage microscopy 
under brightfield and polarized light. As shown in Figure 2B, the crystalline febantel gradually 
dissolves in the Lutrol L44® medium with no residual crystallinity remaining. The liquid 
febantel/Lutrol L44® formulation was stable over several weeks without drug precipitation to 
occur. However, when this liquid was poured in an aqueous medium a translucent gel was 
formed that readily became opaque (Figure 2A3). Fout! Verwijzingsbron niet gevonden.C1-3 
shows optical microscopy images taken at 1 min time intervals of this gelation process. Drug 
precipitates were formed that gradually grow over time. The optical microscopy image in 
Figure 2C4, recorded under polarized light, clearly demonstrated the crystalline nature of 
these precipitates. Most likely, Lutrol L44® micelles are unable to quickly solubilize the 
amount of febantel present. 
A second step in the formulation strategy, aimed to resolve the issue of instantaneous drug 
precipitation upon contact of the febantel/Lutrol L44® solution with water, via coacervation. 
Therefore, the febantel/Lutrol L44® solution was poured into a concentrated (i.e. 42 % (w/w)) 
aqueous maltodextrin solution. It is known that at elevated concentration, aqueous solutions 
of macromolecular and/or amphiphillic species (as are Lutrol L44® and maltodextrin) phase 
separate, forming a so-called simple coacervate [19]. The febantel/Lutrol L44® solution was 
added to a 42 % (w/w) aqueous maltodextrin solution under vigorous stirring. Immediately an 
opaque liquid formed (Figure 3A1), although maltodextrin and Lutrol L44® are both readily 
water-soluble. Optical microscopy revealed that the opacity of the liquid is due to the 
formation of two immiscible liquid phases and not due to precipitation of febantel. When left 
to stand under static conditions, both phases demixed (Figure 3A2-3) and a translucent lower 
phase (about 35 % of the total volume) and a slightly opaque upper phase (about 65 % of the 
total volume) were formed. This two-layer system was stable at room temperature (25 ± 2°C) 
over a period of several months without precipitation of febantel to occur. It is noteworthy that 
in absence of febantel similar phase behaviour was observed. Importantly, when the two-
phase liquid is diluted in aqueous medium, a clear solution is readily obtained (Figure 3B) 
while no drug precipitation is observed. The formulation used in this study contained 5% 
febantel dissolved in a system with 35% Lutrol L44® and 60% aqueous phase (consisting of 
58% water and 42% maltodextrin).  
In order to get a better insight into the nature of the two phases, we spiked before mixing the 
febantel/Lutrol L44® and the aqueous maltodextrin phase, with two different fluorescent dyes. 
Rhodamine B octadecyl ester (red fluorophore) was used as hydrophobic dye and is 
expected to be distributed in the same way as febantel while FITC-dextran (green 
fluorophore) was used as hydrophilic dye that is expected to be distributed in the same way 
as maltodextrin. Upon mixing of both phases, an opaque liquid forms (Figure 4A) which 
slowly phase-separates over time, similarly as described above for the non-fluorescent 
labelled sample. After 8h, two distinct phases were formed with the lower phase stained 
yellow and the upper phase stained red. This gives a strong indication that maltodextrin will 
be preferentially distributed in the lower phase while febantel will be distributed in the upper 
phase. Further insight into the formation of both phases was gained via optical microscopy 
by recording images immediately upon mixing of the febantel/ Lutrol L44® and the 
maltodextrin phases. As shown in Figure 4B, a two-phase system is formed, composed of a 
discrete phase containing the hydrophobic (red) fluorescent marker and a continuous phase 
containing the  hydrophilic (green) fluorescent marker.  
These observations indicated indeed that upon contact with the aqueous maltodextrin phase, 
the febantel/Lutrol L44® phase withdraws water from the aqueous maltodextrin phase, 
forming a colloidal gel with febantel distrbuted within its hydrophobic domains. . It is known 
that at elevated concentration macromolecular species tend to phase separate [20]. In this 
particular case, the maltodextrin aids the formation of the coacervate by reducing the 
solubility of the Lutrol L44®. To confirm this hypothesis we analysed the composition of the 
lower and upper phase by 1H-NMR spectroscopy. Figure 5 shows the NMR spectra of the 
upper and lower phase as well as the spectra of the individual components. As febantel is 
poorly water-soluble, but soluble in methanol, and maltodextrin is soluble in water but not in 
methanol, we recorded the respective 1H-NMR spectra either in deuterated water (D2O) or 
deuterated methanol (d4-MeOH), respectively. From the respective spectra in Figure 5, it is 
clear that febantel is exclusively distributed in the upper phase. Lutrol L44® is predominantly 
found in the upper phase, but also, to a lesser extent in the lower phase. Furthermore, 
maltodextrin was abundantly present in the lower phase but also to a limited extent in the 
upper phase. Also D2O was observed in the spectrum of the upper phase that was recorded 
in d4-MeOH, this attributed to the hypothesis that Lutrol L44® was present as a colloidal gel 
with febantel solubilized in the hydrophobic micellar domains. Quantification of the febantel 
concentration in the upper coacervate phase via HPLC indicated that the drug concentration 
was 7.5%. 
For dissolution experiments, hard-gelatin capsules were filled with coacervate and added to 
dissolution vessels containing demineralized water thermostatized at 37.5 °C. Worthwhile to 
note is that these capsules were stable at room temperature without changes over a period 
of several weeks, likely due to the small amount of water that is contained within the 
coacervate phase. The dissolution data (Figure 6) showed clear differences between the 
release rate of febantel from the coacervate system and from the Rintal® granules: after 20 
min 83.4 ± 1.6 % of the febantel load was released from the capsules containing the 
coacervate formulation, whereas febantel release was limited to 19.9 ± 6.0 % from capsules 
containing the granules (Figure 6). The poor performance of Rintal® in the experimental in 
vitro set-up is likely due to the crystalline nature of febantel within this formulation, whereas 
febantel is solubilised in the coacervate-based formulation The reduction in cumulative drug 
release at 20 min is possibly due to supersaturation of the drug in the dissolution vessel.  
Figure 7 shows the mean plasma concentration-time profiles of febantel and the active 
metabolites (fenbendazole and oxfendazole) after oral administration of both formulations to 
dogs, while the pharmacokinetic parameters are reported in Table 1. The coacervate system 
enhanced absorption and improved bioavailability of febantel in dogs as the AUC0-24h values 
of febantel and fenbendazole after administration of the coacervate formulation were 
significantly different (P < 0.05) from the Rintal® granules. However, AUC0-24h of oxfendazole 
was not significantly different (P > 0.05) between both formulations.   
 
 
 
 
 
 
 
 
 
 
 
4 CONCLUSIONS 
Coacervation proved to be promising as formulation strategy for poorly water-soluble drugs. 
The in-vitro results showed a significant increase in febantel release from the coacervate 
system compared to conventional granules. This was confirmed by the in-vivo study, as a 
significant increase in febantel concentration and fenbendazole was observed from the 
coacervate system compared to the granules. Further studies are required to transform the 
coacervate system into a solid dosage form and to assess the applicability of this concept for 
other poorly water-soluble drugs. 
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